Merck Millipore celebrates 40 years of first class sterility testing solutions
In 1974, Merck Millipore was the first to market a closed filtration device: Steritest?. Since this time, through dedicated research & development, we have been instrumental in raising the industry?s standards ? reducing the risk of false positive and negative results, increasing reliability and improving workflow for microbiologists around the world.
Merck Millipore celebrates 40 years of first class sterility testing solutions
In 1974, Merck Millipore was the first to market a closed filtration device: Steritest™. Since this time, through dedicated research & development, we have been instrumental in raising the industry's standards – reducing the risk of false positive and negative results, increasing reliability and improving workflow for microbiologists around the world.
We are a one-stop shop that offers an extensive portfolio of quality control products, as well as preventive maintenance, training, validation support and much more.
As we step into the future, Merck Millipore will continue providing reliable high quality products and comprehensive first-class services.
Our latest offer: a rapid sterility testing solution providing results within only 5 days.
40 years is just the beginning
www.merckmillipore.com/40years-steritest
“Conducting a test for sterility requires excellent work flows and a reliable test performance. The Merck Millipore SteritestTM system, with pump and filtration devices, supports the operators in a perfect manner to obtain reliable test results.”
Dr. Timo Krebsbach, Divison Manager Marketing & Sales, Labor L+S AG
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
